Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • Aumento selectivo de vesículas extracelulares derivadas de cardiomiocitos después de un infarto de miocardio experimental y efectos funcionales en el endotelio

    Rodriguez JA (1), Orbe J (1), Saenz-Pipaon G (2), Abizanda G (3), Gebara N (2), Radulescu F (2), Azcarate PM (4), Alonso-Perez L (4), Merino D (5), Prosper F (6), Paramo JA (7), Roncal C (8).

    (1) Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA)-University of Navarra, Spain; CIBERCV, Madrid, Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Spain.
    (2) Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA)-University of Navarra, Spain.
    (3) IdiSNA, Instituto de Investigación Sanitaria de Navarra, Spain; Hematology Service, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (4) Departamento de Cardiología, Hospital San Pedro, Logroño, Spain.
    (5) Flow Cytometry and Cell Sorting Core, Health Research Institute-IDIVAL, Santander, Spain.
    (6) IdiSNA, Instituto de Investigación Sanitaria de Navarra, Spain; Hematology Service, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain; CIBERONC, Madrid, Spain.
    (7) Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA)-University of Navarra, Spain; CIBERCV, Madrid, Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Spain; Hematology Service, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (8) Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA)-University of Navarra, Spain; CIBERCV, Madrid, Spain; IdiSNA, Instituto de Investigación Sanitaria de Navarra, Spain

    Thrombosis Research 01 de AGOSTO de 2018

  • Desregulación de la adipoquina y la inflamación del tejido adiposo en la obesidad humana

    Unamuno X (1,2), Gómez-Ambrosi J (1,2,3), Rodríguez A (1,2,3), Berrecil S (1,2,3), Frühbeck G (1,2,3,4), Catalán V (1,2,3).

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
    (3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
    (4) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.

    European Journal of Clinical Investigation 11 de JULIO de 2018

  • Perspectivas en inmunoterapia: informe de la reunión del puente de inmunoterapia

    Ascierto PA (1), Brugarolas J (2), Buonaguro L (3), Butterfield LH (4), Carbone D (5), Daniele B (6), Ferris R (7), Fox BA (8), Galon J (9), Gridelli C (10), Kaufman HL (11), Klebanoff CA (12), Melero I (13), Nathan P (14), Paulos CM (15), Ruella M (16), Sullivan R (17), Zarour H (18), Puzanov I (19).

    (
    1) Melanoma, Cancer Immunotherapy and Development Therapeutics Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale, Napoli, Italy. paolo.ascierto@gmail.com.
    (2) Kidney Cancer Program, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
    (3) Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale, Napoli, Italy.
    (4) UPCI Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
    (5) College of Medicine, James Thoracic Center, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
    (6) Department of Oncology, "G. Rummo" Hospital, Benevento, Italy.
    (7) Division of Head and Neck Surgery, Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
    (8) Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, USA.
    (9) National Institute of Health and Medical Research (INSERM), Paris, France.
    (10) Unit of Medical Oncology, Hospital "San Giuseppe Moscati", Avellino, Italy.
    (11) Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
    (12) Center for Cell Engineering and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
    (13) Immunology and Immunotherapy Service, Clinica Universidad de Navarra, Pamplona, Navarra, Spain.
    (14) Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
    (15) Department of Microbiology and Immunology Hollings Cancer Center, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA.
    (16) Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
    (17) Medicine Harvard Medical School and Haematology/Oncology Department, Massachusetts General Hospital, Boston, Massachusetts, USA.
    (18) Melanoma Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA.
    (19) Early Phase Clinical Trials Program, Experimental Therapeutics Program, Melanoma Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.

    Journal of Immunotherapy Cancer 11 de JULIO de 2018

  • Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy

    Etxeberria I (1,2,3), Teijeira A (1,2,3), Montuenga LM (2,3,4), Berraondo P (1,2,3), Melero I (5,2,3,6).

    (1) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (3) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
    (4) Program of Solid Tumors, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (5) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (6) Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.

    Cancer Discovery 03 de JULIO de 2018

  • Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C

    Manzardo C (1), Londoño MC (1,2), Castells L (2,3), Testillano M (4), Montero J L (2,5), Peñafiel J (1), Subirana M (1), Moreno A (6), Aguilera V (7), González-Diéguez ML (8), Calvo-Pulido J (9), Xiol X (10), Salcedo M (11), Cuervas-Mons V (12), Sousa JM (13), Suarez F (14), Serrano T (15,16), Herrero JI (2,17), Jiménez M (18), Fernandez JR (4), Giménez C (9), Del Campo S (6), Esteban-Mur JI (2,3), Crespo G (1,2), Moreno A (1), de la Rosa G (19), Rimola A (1,2), Miro JM (1); FIPSE LT-HIV investigators.

    (1) Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona.
    (2) CIBEREHD.
    (3) Hospital Vall d'Hebrón, Universitat Autónoma de Barcelona, Barcelona.
    (4) Servicio de Digestivo. Hospital Universitario Cruces, Barakaldo.
    (5) Hospital Universitario Reina Sofía-IMIBIC Córdoba.
    (6) Hospital Universitario Ramón y Cajal-IRYCIS, Madrid.
    (7) Hospital Universitari La Fe, Valencia.
    (8) Hospital Universitario Central de Asturias, Oviedo.
    (9) Hospital Universitario Doce de Octubre, Madrid.
    (10) Hospital de Bellvitge-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona.
    (11) Hospital General Universitario Gregorio Marañón, Madrid.
    (12) Hospital Universitario Puerta de Hierro, Madrid.
    (13) Hospital Universitario Virgen del Rocío, Sevilla.
    (14) Complejo Hospitalario Universitario, A Coruña.
    (15) Hospital Universitario Lozano Blesa, ISS Aragón, Zaragoza.
    (16) Hospital Universitario Lozano Blesa, Zaragoza.
    (17) Clínica Universidad de Navarra, IdiSNA, Pamplona.
    (18) Hospital Universitario Carlos Haya, Málaga.
    (19) Organización Nacional de Trasplantes, Madrid.

    American Journal of Transplantation 02 de JULIO de 2018

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra